RespireRx Pharmaceuticals — Cortex Pharmaceuticals — Investor Presentation (July 2015)
36 slides from RespireRx Pharmaceuticals's investor presentation, Jul 9, 2015
Slide 1: Cortex Pharmaceuticals, Inc.
E)CuEX PHARMACEUTICALS, INC. Cortex Pharmaceuticals, Inc. July 9, 2015
Slide 2: Forward Looking Statements
PHARMACEUTICALS, INC. iz (OXTEX Forward Looking Statements The matters discussed in this presentation that are not historical facts are "forward- looking statements." Forward-looking statements include, but are not limited to, statements containing the words “believes,” "anticipates," "intends," "ex
Slide 3: Cortex is a leader in the discovery and development of innovative pharmaceuticals
Cortex is a leader in the discovery and development of innovative pharmaceuticals for the treatment of breathing disorders » Sleep Apnea e Obstructive sleep apnea (OSA) — dronabinol ° Central sleep apnea (CSA) - ampakines » Drug-induced respiratory depression (RD) - ampakines ° Semi-acute use — post
Slide 4: Cortex Drug Platforms
Cortex Drug Platforms Cannabinoids * Dronabinol (D9-THC) is a generic FDA-approved drug * Positive Phase 2A data for treatment of obstructive sleep apnea + Phase 2B clinical trial in progress * Method patent licensed from U. Illinois for the treatment of sleep related breathing disorders Ampakines *
Slide 5: Sleep Apnea: A Large Market Opportunity
Sleep Apnea: A Large Market Opportunity » Sleep Apnea e Repetitive episodes of airflow cessation {apnea} or reduction (hypopnea) for more than 10s during sleep e Three types: Obstructive, Central and Mixed » The Sleep Apnea Market is Large e 18 million U.S. adults with moderate or severe sleep apnea
Slide 6: Obstructive Sleep Apnea (OSA)
Obstructive Sleep Apnea (OSA) » Obstructive sleep apnea (OSA) involves a decrease or complete halt in airflow despite an ongoing effort to breathe during sleep ° Occurs when the muscles relax during sleep ° Soft tissue in back of throat collapses and obstructs upper airway » Affects 18 MM adults in
Slide 7: Obstructive Sleep Apnea: Scope of the Problem in the US
Obstructive Sleep Apnea Scope of the Problem in the US Estimated Annual Annual Indicated Disease State us Estimated Cost Drug Therapy Prevalence to Society Expenditures OsaAts 18.0 MM $75.0 Billion $0 Asthma®” 16.4 MM $18.3 Billion $13.5 Billion Hypertension®° 43.2 MM $73.4 Billion $48.5 Billion Dia
Slide 8: CPAP air splint and compliance limitations
Works as an air splint to keep upper airway open during sleep 30% of patients prescribed CPAP never initiate treatment when prescribed a machine Over 50% of patients stop using CPAP in the first year of use; may only wear 3-4h/night
Slide 9: Dronabinol: a Breakthrough Treatment for OSA
Dronabinol: a Breakthrough Treatment for OSA Mechanism of Action ° Dronabinol is (D-9)THC, a cannabinoid agonist Stage of Development ° Schedule III drug available by prescription, low risk of addiction ° Approved for the treatment of anorexia in AIDS patients and nausea and vomiting in cancer patie
Slide 10: Dronabinol Phase 2A Clinical Study in OSA
nabinol Phase 2A Clinical Study in O Randomized, double-blind, placebo-controlled dose escalation study in 22 patients with OSA Randomized to Placebo (N=5) or Dronabinol (N=17) for 21 days ° 2.5, 5 and 10 mg/night studied with weekly dose escalation Overnight polysomnogram (PSG) at baseline, and aft
Slide 11: Dronabinol Reduced the AHI in OSA Subjects
Dronabinol Reduced the AHI in OSA Subjects AHI Mean % Change from Baseline to End © of Treatment 2 40% a < 30% Qa oO 20% o P=0.17 n 10% c Dronabinol wa 0% = ° Placebo — 10% az) P<0.01 5 -20% a co) w -30% 40%
Slide 12: Apnea Suppression as a Function of Dose and Time
Apnea Suppression as a Func of Dose and Time 0 -2 -4 -6 -8 utst Half -12 = 2nd Half -14 -16 n=17 n= 13 n=8 AAHI versus Baseline ' ° The plasma half-life of dronabinol is 2 — 4 hours. 12
Slide 13: Dronabinol Phase 2B Trial in OSA
Dronabinol Phase 2B Trial in OSA ° Ongoing clinical study at 4 major medical centers ° Potentially pivotal for NDA approval ° 120 subjects (40/group, 6 wks dosing) ° Doses: Placebo, 2.5 mg, 10 mg qd ° $5 MM NIH Grant ° Completion by May 2016 | — ;
Slide 14: Protecting Dronabinol in the Marketplace
Protecting Dronabinol in the Marketplace » Issued Method-of-Use patent for dronabinol and OSA e Expires in 2025 » Schedule Ill drug, off-label use monitored by US government, discouraging generic manufacturers from selling off-label » Off-label use of generics and medical marijuana are not covered b
Slide 15: Dronabinol — A Game Changer
Dronabinol — A Game Changer Impact on Patient Commercial Opportunity First drug available for OSA Changes the nature of OSA treatment Ease of Use/Better Patient Compliance Broadly expands prescriber base from sleep specialists to include primary care physicians and cardiologists Low cost Recurring l
Slide 16: Ampakines — A Novel Class of Drugs
AMPAKINES — A NOVEL S OF DRUGS AMPA Receptors Mediate Synaptic Transmission in the Brain » Glutamate is the major excitatory neurotransmitter in the CNS AMPAKINE . » Fast excitatory transmission is * mediated by AMPA-type glutamate he receptors >» Ampakines are positive, allosteric modulators of the
Slide 17: Ampakines — Novel Treatment for Respiratory Depression
AMPAKINES — Novel Treatment for Respiratory Depression PreBétzinger “ PreBotzinger Complex Complex + Neurons in this brainstem region control inspiratory breathing rhythm + PreBotC neurons use AMPA receptors for signaling pes ener eecaeaiee ye cape lees . Opiates and other depressants mediate their
Slide 18: CX1739 Oral Phase Ampakine
1739 ral Phase 2 Ampakin » Stage of Development ° Completed Phase 1 in healthy volunteers and Phase 2a in central sleep apnea e Ready for Phase 2 studies in opiate and propofol induced respiratory depression » Targeted Indications ° Oral therapy for opiate and propofol induced respiratory depression
Slide 19: Central Sleep Apnea
Central Sleep Apnea » Characterized by a lack of drive from the brain to breathe during sleep — similar response as in treatment of RD » Manifestations of CSA e Narcotic-induced central apnea (70% chronic users) ° Heart failure patients (up to 40%) ° Idiopathic CSA (5% sleep apnea patients) » Standa
Slide 20: Severity of CSA is Correlated with Increased Mortality in HF Patients
The Severity of CSA is Correlated with Increased Mortality in HF Patients ~. ma, (6 AHT less than 5 per hour ‘ ‘woe AHL equal or greater than S per hour Reducing Central Sleep Apnea May Reduce Mortality in Heart Failure Patients %. Survival % B86 82828 8 8 ‘Survival of heart failure (HF) patiants wi
Slide 21: CX1739 Sleep Apnea Clinical Study Design
CX1739 Sleep Apnea Clinical Study Design Design Randomized, double-blind, placebo-controlled study Population 20 adults with moderate to severe sleep apnea (16 given CX1739; 4 given Placebo) Dosing Each subject receives either placebo or a single dose of 900mg CX1739 one hour before lights out Prima
Slide 22: Apnea-Hypopnea Response to CX1739
Apnea-Hypopnea Response to CX1739 Apnea-Hypopnea Index CX1739 3/15 (AHI) Placebo 0/4 Apnea-Hypopnea Time CX1739 5/15 a) Placebo 0/4 Why do some patients respond, and others not ? * A responder has at least a 40% decrease in the respective parameter | >
Slide 23: CX1739 Was More Effective on Mixed and Central Sleep Apneas
CX1739 Was More Effective on Mixed and Central Sleep Apneas Obstructive Apneas Mixed Apneas Central Apnea 12 6. 5 10: yo go xm oT ot ot 3 SE4 SE 8 EG 2 zs = st 6 £3. we 6 25 15 35 35 es 2s 2s ary Si 2 ai 4 Zu gu ou o 0. 0. se + r r N Ron ye
Slide 24: Acute Drug-induced Respiratory Depression
Acute Drug-induced Respiratory Depression + Most frequent lethal side effect of opiate use is respiratory depression (RD) * In-patient, post-surgical opiate use (~12M patients/year) increases risk for RD * RD also occurs during surgery and procedures (e.g., soloncseopy) that use propofol as an anest
Slide 25: Respiratory Failure: A Very Serious Hospital Safety Problem
Respiratory Failure: A Very Serious Hospital Safety Problem HeatthGrades Patient Safety in American Hospitals Study 2010 - 28 ‘Appendix E: Patient Safety Events and Attributable Mortality and Excess Charge Appendix E: Patient Safety Events and Their Attributable Mortality and Excess Charge Among Med
Slide 26: Reversal of Opioid-induced Respiratory Depression with an Ampakine in Rats
Reversal of Opioid-induced Respiratory Depression with an Ampakine in Rats CX1739 injection Fentanyl 10s Prolonged opiate-induced CX1739 reverses opiate-induced respiratory depression leads to respiratory depression and prevents lethality lethality 26
Slide 27: Reversal of Propofol-induced RD with an Ampakine in the Rat
Reversal of Propofol-induced RD With an Ampakine in the Rat Experimental Design: — Administer a lethal dose of propofol to rats — Inject CX1739 within 1 minute Propofol OO Propofol + CX1739 {NINN * s,s), 7
Slide 28: Opioid-induced Respiratory Depression in Humans
Depression in Arnane » Two clinical studies were run in normal, healthy volunteers with CX717 an earlier Ampakine » Moderate respiratory depression was induced experimentally by infusion of the opioid, Alfentanil » Respiratory and analgesia end-points were measured properties of the opioid
Slide 29: CX717 reverses alfentanil-induced respiratory depression
C—Placebo ag CX717 NORMAL---< £ *P<0.01 RD <8 BPM ---& NS - Not Significant $ a Baseline +Alfentanil +Naloxone Data are expressed as the basal respiratory rate. N= 15 and 16 per group. CX717 dose is 1500mg. 29
Slide 30: CX717 Maintains Analgesic Properties of Opioids
X717 Maintains Analgesic Properties of Opioids (“Placebo 2 15: macx717 = @ 5 1.0 NS 2) = S Delivery of a electrical a 0.5: stimulation to finger 0.0: Baseline +Alfentanil +Naloxone + Alfentanil reduced the pain sensitivity (produced analgesia) + Analgesia was unaffected by CX717 Data are expressed a
Slide 31: CX1942: A Soluble Ampakine
CX1942: A Soluble Ampakine » Mechanism of Action ° Positive Allosteric Modulator of AMPA receptors ° Water-soluble - allowing for injectable dosage forms » Stage of Development e Injectable routes have been studied in animal models of respiratory depression ° Exploratory studies supported by SBIR co
Slide 32: Status of Product Pipeline - Respiratory Disorders
Status of Product Pipeline - Respiratory Disorders Depression (injectable) Stage of Development Indication Compound ee ites [ed [|g Obstructive Sleep Apnea Dronabinol — Central Sleep Apnea in CHF | CX1739 (xasssesapannnnnnennsny’ a oe TT Drug-induced Respiratory x1942 —_—— 32
Slide 33: Key Objectives for the Next Months
Key Objectives for the Next 12 Months Compound Dronabinol CX1739 CX1739/C X717 CXx1942 (Pending Availability of Finance) Indication Obstructive Sleep Apnea Opiate-induced RD Propofol-induced RD Pompe Disease, Spinal Cord Injury, other Injectable for RD Status Phase IIB Phase IIA Phase IIA Phase IIA
Slide 34: Summary
Summary * Two drug platforms * Three Phase 2 or Phase 2 ready programs + Blockbuster markets + IP protection with the ability to add additional IP + Low valuation entry point + Experienced management team ¢ Strategic collaborative opportunities + Availability of non-dilutive finance + Public company
Slide 35: Background
Background 2013 + Insolvent and near bankruptcy No ongoing operations Lost dronabinol license Deficient in SEC reporting Approx. $3M market cap Today + Non-bankruptcy reorganization New capital raised Re-gained dronabinol license Current in SEC reporting Approx. $15M market cap Newly organized resea
Slide 36: Management and Directors
Management and Directors Arnold Lippa Jeff Margolis Robert Weingarten Richard Purcell John Greer Katie MacFarlane James Sapirstein Chairman, CEO VP, Sec/Treas, Director CFO, Director Senior VP R&D Chairman, Scientific Advisory Board Prof & Dir. Neuroscience Ctr., U. Alberta Director, CCO Agile Thera
Cortex Pharmaceuticals — Investor Presentation (July 2015) on 6ix